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Abstract
X-linked Charcot-Marie-Tooth disease (CMT1X) is a common form of inherited neuropathy resulting from different
mutations affecting the gap junction (GJ) protein connexin32 (Cx32). A subset of CMT1X patients may additionally
present with acute fulminant CNS dysfunction, typically triggered by conditions of systemic inflammation and
metabolic stress. To clarify the underlying mechanisms of CNS phenotypes in CMT1X we studied a mouse
model of systemic inflammation induced by lipopolysaccharide (LPS) injection to compare wild type (WT),
connexin32 (Cx32) knockout (KO), and KO T55I mice expressing the T55I Cx32 mutation associated with CNS
phenotypes. Following a single intraperitoneal LPS or saline (controls) injection at the age of 40–60 days
systemic inflammatory response was documented by elevated TNF-α and IL-6 levels in peripheral blood and
mice were evaluated 1 week after injection. Behavioral analysis showed graded impairment of motor performance in
LPS treated mice, worse in KO T55I than in Cx32 KO and in Cx32 KO worse than WT. Iba1 immunostaining revealed
widespread inflammation in LPS treated mice with diffusely activated microglia throughout the CNS. Immunostaining
for the remaining major oligodendrocyte connexin Cx47 and for its astrocytic partner Cx43 revealed widely reduced
expression of Cx43 and loss of Cx47 GJs in oligodendrocytes. Real-time PCR and immunoblot analysis indicated
primarily a down regulation of Cx43 expression with secondary loss of Cx47 membrane localization. Inflammatory
changes and connexin alterations were most severe in the KO T55I group. To examine why the presence of the
T55I mutant exacerbates pathology even more than in Cx32 KO mice, we analyzed the expression of ER-stress
markers BiP, Fas and CHOP by immunostaining, immunoblot and Real-time PCR. All markers were increased in
LPS treated KO T55I mice more than in other genotypes. In conclusion, LPS induced neuroinflammation causes
disruption of the main astrocyte-oligodendrocyte GJs, which may contribute to the increased sensitivity of Cx32
KO mice to LPS and of patients with CMT1X to various stressors. Moreover the presence of an intracellularly
retained, misfolded CMT1X mutant such as T55I induces ER stress under inflammatory conditions, further exacerbating
oligodendrocyte dysfunction and pathological changes in the CNS.
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Introduction
X-linked Charcot-Marie-Tooth (CMT) disease (CMT1X),
associated with over 400 different mutations in the GJB1
gene, is one of the commonest forms of inherited neu-
ropathies (http://www.molgen.ua.ac.be/CMTMutations/)
[8, 28]. GJB1 encodes connexin32 (Cx32), a protein that
forms gap junctions (GJs) both in Schwann cells in the
peripheral nerves and in oligodendrocytes throughout the
CNS, among other tissues [1, 59]. CMT1X patients
present with slowly progressive weakness and atrophy
usually starting in distal leg muscles, causing difficulty in
running and frequently sprained ankles, typically begin-
ning by 10 years of age. Males are earlier and more
severely affected than heterozygous females who may be
asymptomatic or may have a milder clinical form of the
disease at an older age [26].
CMT1X mutations have been associated with clinical
CNS phenotypes in addition to peripheral neuropathy,
including chronic corticospinal tract dysfunction mani-
festing with spasticity, extensor plantar responses and
hyperactive reflexes in patients with the A39V [38], T55I
[50], M93V [7], R164Q [50], R164W [20], R183H [9],
T191 frameshift [31] and L143P [30] mutations. Subclin-
ical evidence of CNS involvement, such as abnormal
brainstem auditory, visual, and motor evoked responses
[6], is seen in a high proportion of cases [44, 45]. Acute
transient encephalopathy, along with MRI changes, has
been described in CMT1X patients carrying the M1L,
T55I, R75W, E102del, R142W, R142Q, R164W,
R164Q, C168Y and V177A mutations [49, 52, 65]. In
most cases encephalopathy occurred under conditions
of metabolic stress such as traveling to high attitudes
[52], febrile illness [18, 58], hyperventilation [63] or
concussion [2, 17]. CNS dysfunction caused by GJB1
mutations is more common in children and young
adults [2] without correlation to the stage and severity
of the peripheral neuropathy.
The cellular mechanisms leading to CNS phenotypes
in a subset of CMT1X patients remain unclear. Connex-
ins are synthesized in the endoplasmic reticulum (ER),
transported to the Golgi apparatus and then inserted as
hexamers into the cell membrane [42]. Both in vivo and
in vitro studies of CMT1X mutations have shown that
many mutants are retained in the ER or Golgi with re-
duced or absent formation of GJ plaques at the cell
membrane, [29, 75] and these missfolded mutants are ef-
fectively degraded by proteasomes and lysosomes [70].
Impaired formation of GJs by mutant Cx32 molecules
and the loss of Cx32 function is responsible for the de-
velopment of the neuropathy in most CMT1X mutations
[26] with the exception of rare reports of toxic mutants
associated with severe neuropathy phenotypes [33]. A
gain-of-function mechanism for CNS manifestations has
been considered both because patients with complete
lack of the coding sequence have no subclinical CNS
manifestations [16, 64] and because a disproportionate
fraction of the mutations associated with the florid man-
ifestations are represented in more than one pedigree,
suggesting that specific mutations are particularly prone
to cause this syndrome. Nevertheless, an ADEM-like
CNS phenotype has been recently reported in a patient
with start codon GJB1 mutation [24] leading to complete
loss of Cx32 synthesis [56], suggesting that loss of Cx32
function alone is sufficient to account for the CNS phe-
notypes in CMT1X.
Although trans-dominant effects of Cx32 mutants on
co-expressed oligodendrocyte connexins Cx47 and Cx29
have been hypothesized, we found no interaction in vivo
of two representative Cx32 mutants showing retention
in the ER (T55I) or Golgi (R75W) with other connexins
expressed in oligodendrocytes [57]. However, these
mice were not subjected to stressful conditions as de-
scribed in some CMT1X patients, and toxic effects
only manifesting under stress conditions such as neuroin-
flammation may have been missed. Pro-inflammatory cy-
tokines may disrupt glial GJs both by affecting connexins
in astrocytes [10, 23], as well as in oligodendrocytes [36].
In the case of CMT1X patients and related models, this
could further exacerbate the already tenuous GJ coupling
of oligodendrocytes, leading to clinical manifestations.
To further clarify the cellular mechanisms underlying
the CNS phenotypes in patients with CMT1X, we used a
model of systemic inflammation induced by lipopolysac-
charide (LPS) injection comparing wild-type (WT) mice,
Cx32 knockout (KO) mice, and Cx32 KO expressing the
T55I mutant of Cx32 (KO T55I). We hypothesized that
dominant effects of the T55I mutant might only become
manifest under stress conditions that mimic the meta-
bolic and inflammatory events leading to encephalopathy
in CMT1X patients. We found that a combination of
cellular alterations, both mutant-related but also inde-




Adult male (p40–p60) mice were used for this project
and kept under standard housing conditions with a
12 hours (h) dark/light cycle and with food and water
provided ad libitum. All experiments were performed in
accordance with the animal care protocols approved by
the Cyprus Government’s Chief Veterinary Officer ac-
cording to EU guidelines. Three genotypic groups were
used (n = 26 per group): Wild type (WT), connexin32
knockout (Cx32 KO), and Cx32 KO expressing the
T55I mutant (KO T55I) associated with CMT1X. The
KO T55I mutant was generated by pronuclear injec-
tion of the transgenic cassette described in [57] on a
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Bl6/N background and then crossed with the back-
crossed Cx32 KO line. The WT was a 6 N and the
Cx32 KO (originally generated by Prof. Klaus Willecke,
University of Bonn, Bonn, Germany) was backcrossed
at least 12 times to ensure a similar genetic back-
ground for the purpose of comparing the response to
LPS. Only male animals were used for this study.
Determination of Genotypes
Genotypes were identified by PCR of genomic tail DNA
with specific primers for the Cx32 KO allele: Exon1F
(5’- GACCACTCCCCCTACACAGA-3’), Cx32R (5’- CGC
TGTTGCAGCCAGGCTGG-3’) resulting in a 732 bp PCR
product (94 °C × 5 min, 40 cycles of 94 °C × 30 s, 57 °C ×
30 s, 72 °C × 30 s and then 72 °C × 7 min) and Exon1F
(5’-GACCACTCCCCCTACACAGA-3’), NeoR2 (5’-CT
CGTCCTGCAGTTCATTCA-3’) resulting in a 721 bp
PCR product (94 °C × 5 min, 35 cycles of 94 °C × 30 s,
56 °C × 30 s, 72 °C × 30 s and then 72 °C × 7 min). For
the KO T55I, all primers specific for the Cx32 KO were
used, and in addition the CNP1F (5’- TGTGGCTT
TGCCCATACATA-3’), Cx32R (5’-CGCTGTTGCAGC
CAGGCTGG-3’), resulting in a 732 bp PCR product
(94 °C × 5 min, 40 cycles of 94 °C × 30 s, 57 °C × 30 s,
72 °C × 30 s and then 72 °C × 7 min) and Cx32F (5’- CG
CTGTTGCAGCCAGGCTGG-3’), EGFPR1 (5’- GCTG
AACTTGTGGCCGTTTA-3’), resulting in a 785 bp
PCR product.
LPS model
Lipopolysaccharide (LPS) from Escherichia coli (E. coli)
(serotype 0127:B8) was purchased from Sigma Chemical
(St. Louis, MO) and 150 μl (LPS stock concentration
1 μg/mL, 7.5 mg/Kg injected LPS) were injected once
intraperitonealy (i.p) to induce a systemic inflammatory
response. Sterile saline i.p injection was used as control
treatment for all experiments. Animals were weighted
daily until the day of sacrifice (7 days after injection) and
were observed for any sickness behavior.
ELISA
Approximately 100 μl of blood was collected from the
vein with a glass micropipette, at different time-points
(just before saline/LPS injection, as well as 4, 24 and
96 h after injection). For blood collection mice were po-
sitioned under warm light for five minutes prior to blood
collection in order to increase blood flow and then
placed in a restraining tube so that their head and body
were restrained, leaving only the tail outside the tube.
Using sharp scissors, approximately 1 cm of the tail was
removed and blood was collected in a capillary tube as
drops appeared. Pressure was applied to stop the bleed-
ing and for further collection the original wound was re-
opened by removing the clot. Following blood collection,
blood was incubated at 37 °C for 20 min in the heat
block, stored overnight at 4 °C, subjected to centrifuga-
tion at 3000 rpm for 10 min and then stored in aliquots
at −80 °C. Expression levels of plasma pro-inflammatory
cytokines, tumor necrosis factor alpha (TNF-α) and
Interleukin-6 (IL-6) were evaluated in LPS and saline
treated animals in order to confirm the induced inflamma-
tory response upon LPS injection. ELISA was performed
using the Mouse TNF alpha ELISA Ready-SET-Go!®
(eBioscience) for the detection of mouse TNF-α and the
Mouse IL-6 ELISA Ready-SET-Go!® (eBioscience) kit for
the detection of mouse IL-6.
Behavioral analysis
Foot slip test
The method of Britt et al. [11] modified for mice was used
in order to assess motor co-ordination. Approximately 4 h
after injection mice were placed in a 15 × 15 × 15 cm clear
plexiglass box with a floor consisting of a metal wire grid
with 1.25 cm spacing with a 1.25 cm grid suspended
1.25 cm above the floor. A trial consisted of 50 steps. If a
misstep resulted in the hindlimb falling through the grid
but the limb was withdrawn prior to touching the floor it
was scored 1; if the limb touched the floor it was scored 2.
A video camera was used to film the mice. Mice were accli-
mated by performing a trial on each of 3 consecutive days
prior to injection and for 60 min in the box prior to testing.
Rotarod analysis
Four hours after saline/LPS injection mice were tested
for motor balance and co-ordination. Animals were
placed on a 3.5 cm diameter rod, rotating at a constant
speed of 12 rpm and the time took for the animal to fall
off was recorded using a timer. Mice were left to rest for
15 min and then tested at 20 rpm. Mice were trained on
the rotarod for 3 trials of 3 consecutive days prior to in-
jection. Mice were also acclimated to the testing room
for 60 min before each session.
Immunoblot analysis
For immunoblot analysis, saline- and LPS-injected ani-
mals (n = 4 per treatment condition from each genotypic
group) were sacrificed 7 days after injection and fresh
tissues (brainstem and cerebellum) were harvested and
lysed in ice-cold RIPA buffer (10 mM sodium phosphate
pH 7.0, 150 mM NaCl, 2 mM EDTA, 50 mM sodium
fluoride, 1 % NP-40, 1 % sodium deoxycholate, and
0.1 % DSD) containing a mixture of protease inhibitors
(Roche). Tissues were then sonicated 5 × 5 s and protein
concentrations were measured with Nanodrop at λ = 280.
Proteins (100 μg) from tissue lysates were fractionated by
12 % SDS-PAGE and then transferred to a Hybond-C
extra membrane (GE Healthcare Bio-Sciences), using a
semi-dry transfer unit (GE Healthcare Bio-Sciences). The
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membrane was blocked for 1 h at room temperature
(RT) with 5 % non-fat skimmed milk in Tris-buffered
saline containing 0.1 % Tween-20 (TBS-T). Immuno-
blots were then incubated with the following anti-
bodies: rabbit anti-Iba1 (BioCare, diluted 1:500), rabbit
anti-BiP (Santa Cruz, diluted 1:1000), mouse anti-
Cx43 (Millipore, diluted 1:1000), rabbit anti-Cx47
(1:20,000, [47]) or mouse anti-MBP (Abcam, diluted
1:5000) in 5 % non-fat skimmed milk in TBS-T, over-
night at 4 °C. Following three 15 min washes in TBS-T,
immunoblots were incubated for 1 h at RT with an
anti-mouse or anti-rabbit HRP-conjugated secondary
antiserum (Jackson ImmunoResearch Laboratories) di-
luted 1:3000) in 5 % non-fat skimmed milk in TBS-T.
All membranes were reprobed with either GAPDH
(Santa Cruz Biotechnology, diluted 1:3000) or tubulin
(Developmental Studies Hybridoma Bank diluted 1:4000)
to demonstrate the loading. The bound antibody was visu-
alized by enhanced chemiluminescence system (ECL, GE
Healthcare Bio-Sciences) and band intensity was quanti-
fied using Tinascan software after normalizing each band
to the GAPDH or tubulin band intensity.
Immunohistochemistry
For immunofluorescence staining, saline- and LPS-
injected animals (n = 5 per treatment condition from
each genotypic group) were sacrificed 7 days after injec-
tion. Mice were anesthetized with Avertin according to
institutionally approved protocols and then transcar-
dially perfused with saline followed by addition of 4 %
paraformaldehyde (PFA) in 0.1 M PB. Tissues (midbrain,
brainstem, cerebellum and spinal cord) were harvested
and fixed for 30 min followed by cryoprotection in 20 %
sucrose in phosphate buffer (PB) overnight. Tissues were
then embedded in optimum cutting temperature com-
pound (OCT), placed in ice cold acetone and stored at
−80 °C. Twelve μm thick sections were thaw-mounted
onto glass slides, permeabilized in cold acetone (−20 °C
for 10 min), and incubated for 1 h at RT with blocking
solution (5 % bovine serum albumin - BSA) containing
0.5 % Triton-X. The primary antibodies diluted in block-
ing solution were incubated overnight at 4 °C: mouse
Cx43 (Millipore, 1:200), CC1 (Calbiochem 1:50), GFAP
(Sigma, 1:200), RT97 (Hybridoma Bank, 1:1000), MOG
(Dr. Sara Piddlesden, Cardiff, 1:200) and MBP (Abcam,
1:500), and rabbit antisera against Cx47 (Invitrogen,
1:500), Iba1 (BioCare, 1:500), activated caspase-3 (BioVi-
sion, 1:100), Fas (Santa Cruz, 1:200), CHOP/GADD153
(Santa Cruz, 1:50), BiP (Santa Cruz, 1:50), Fibrinogen
(Dako, 1:100) and Fibronectin (Dako, 1:500). Sections
were then washed in PBS and incubated with rhodamine
(TRITC) conjugated affinity purified goat anti-rabbit
IgG and fluorescein (FITC) conjugated affinity purified
goat anti-mouse IgG secondary antibodies (Jackson
ImmunoResearch Laboratories, 1:500) for 1 h at RT.
Cell nuclei were visualized with 4’, 6’-diamidino-2-phe-
nylindole (DAPI) (Sigma-Aldrich). Slides were mounted
with Dako fluorescent mounting medium and images
were photographed under a Zeiss fluorescence micro-
scope with a digital camera using the Zeiss Axiovision
software (Carl Zeiss MicroImaging). For Cx47 localization
some images were also taken with a Leica DMR confocal
microscope (Leica Microsystems).
Assessment of inflammatory cell infiltrates
Spinal cord roots and sciatic nerves of saline and LPS
injected animals were also harvested as described above
in order to assess the existence of inflammatory cell
infiltrates (lymphocytes and macrophages) in the periph-
eral nervous system with immunohistochemistry. Rabbit
antiserum against T-cell marker CD3+ (Santa Cruz, diluted
1:100) and fluorescein conjugated rat antiserum against
macrophage marker CD68+ (Serotec, diluted 1:50) were
used as primary antibodies.
Morphometric analysis
Immunostained coronal sections of brainstem, cerebel-
lum and spinal cord were visualized and captured with
an AxioHR camera. Images of Iba1, MBP, MOG, and
GFAP, immunostained sections were captured at 200×
final magnification whereas images of connexin and CC-
1 stained sections were captured at 400× final magnifica-
tion. To assess microglial activation we measured the
total area of Iba1 immunofluorescence and for myelin
density evaluation we measured the total area of MBP
immunofluorescence with ImageJ software, and results
were presented as percentage of total image area. Oligo-
dendrocyte numbers per total area were counted in
CC-1 stained sections.
Quantification of GJ plaques formed by Cx47 and Cx43
Quantification of GJ plaques (defined as a focal accu-
mulation of connexin immunoreactivity and size set
between 0.01 and 1 μm2 for Cx43, and between 0.01
and 2 μm2 for Cx47) was performed within a 9620 μm2
area using Image Pro 6.3 software in spinal cord gray
and white matter and in brainstem sections stained
with antibodies against Cx43 and Cx47 as described
previously [36]. The total number of GJ plaques
formed by Cx43 and Cx47 was measured. In addition,
we counted the total number of oligodendrocytes la-
beled with the CC1 antibody in the same areas, and
also quantified the number of Cx47 GJ plaques per
oligodendrocyte in a fixed area of 30x30μm. All results
of morphometric analysis were compared between LPS
and saline treated mice in each genotype as well as
between genotypes.
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RNA extraction and quantitative Real-Time PCR
RNA was isolated from the brainstem using the RNeasy
Lipid Tissue Mini Kit (Qiagen, Germany) according to
manufacturer instructions using the Qiazol Lysis Re-
agent followed by DNase treatment. RNA samples were
quantified by spectrophotometry (Nanodrop ND_100)
and subjected to reverse transcription (RT)-PCR (25 °C
for 10 min, 48 °C for 30 min, and 95 °C for 5 min) using
the TaqMan RT-PCR Reagents and a GeneAmp PCR
System (Applied Biosystems, Singapore) (end volume of
40 μL). The expression levels of genes encoding Cx47,
Cx43 and BiP were assessed by quantitative Real-Time
PCR Analysis (hold at 55 °C for 2 min and at 95 °C for
10 min, followed by 40 cycles at 95 °C for 15 s and at
60 °C for 1 min) using a 7900HT Real-Time PCR System
(Applied Biosystems) and Taq-Man© Gene Expression
Assays: Cx43: Mm01179639_s1; Cx47 Mm00519131_s1;
BIP: Mm00517691_m1, Tubulin (Mm00726185_s1) was
used as endogenous “house- keeping” control gene.
Each sample was loaded in triplicate and contained
250 ng of cDNA, 1 μl of TaqMan Gene Expression
Assay, and 10 μl of TaqMan Gene Expression Master
Mix (end volume 20 μl). Expression levels in LPS and
saline control mice were calculated after normalizing
cycle thresholds against tubulin and presented as the
fold induction value (2–D DCt) relative to naive control
mice (mean ± standard deviation).
Statistical analysis
All data were expressed as the mean, standard deviation
SD; standard error of the mean (SEM), and statistical sig-
nificance was assessed with the two-tailed Student’s t-test
followed by Bonferroni's correction when multiple com-
parisons were performed, using Microsoft Excel software.
A value of p < 0.05 was considered statistically significant.
Results
Establishment of the LPS-induced systemic inflammation
model
The CNS phenotypes in CMT1X patients are frequently
triggered by febrile illness [2, 58, 65]. In order to study
this we developed a model of LPS-induced systemic in-
flammation. Intraperitoneal (i.p.) injection of LPS (150 μl)
induced a systemic inflammatory response characterized
by sickness behavior with transient mild weight loss (1.7 ±
0.64 gr at 24 h post injection), lethargy, isolation, and re-
duced mobility in the first 2 days after injection, followed
by recovery of mobility back to normal levels. ELISA
confirmed a marked increase of two pro-inflammatory cy-
tokines, TNF-α and IL-6, 4 h after injection in peripheral
blood of Cx32 KO LPS-injected as opposed to saline-
injected mice (Additional file 1: Figure S1).
Systemic inflammation was associated with a dif-
fuse CNS inflammatory response, demonstrated by
immunohistochemistry for Iba1, a microglia marker.
Compared to saline injected control mice, in LPS-
injected mice microglia were diffusely activated in all
CNS areas examined including the spinal cord, brain,
brainstem and cerebellum (Fig. 1a–f and Additional
file 2: Figure S2). Quantification of Iba1 immunore-
activity (n = 5 animals per treatment group) con-
firmed that microglia were significantly activated in
the CNS of LPS treated mice compared to controls,
in all genotypes and in all areas studied (Fig. 1g–j).
Even at baseline in saline groups there was increased
Iba1 immunoreactivity in T55I KO compared to KO
and WT mice suggesting that more activated microglia
are present (Additional file 3: Table S1). The immuno-
staining findings were further corroborated by immu-
noblot analysis of Iba1 levels. Compared to saline
treated mice, LPS-injected mice showed significantly
elevated Iba1 levels in all genotypes studied, including
the WT, Cx32 KO, and KO T55I mice (Fig. 1k, l). The
highest LPS-induced Iba1 increase was found in KO
T55I mice, both by immunostaining and by immunoblot
suggesting that inflammation in exacerbated by the
presence of the T55I mutant, which is retained in the ER
[29, 57], as confirmed by double labeling with ER marker
BiP (Additional file 4: Figure S3). In contrast to CNS, we
could not detect any significant inflammatory changes
in the peripheral nervous system after LPS injection in
these 2-month old Cx32 mutant mice, in which periph-
eral nerve pathology begins after the age of 3 months
[5, 57, 60]. Immunostaining for macrophages (CD68)
and T-cells (CD3) failed to show any differences com-
pared to saline controls in sciatic nerves or lumbar
spinal roots (Additional file 5: Figure S4). Thus, Cx32
KO mice show a higher degree of baseline CNS in-
flammation and a stronger CNS inflammatory reac-
tion to LPS-induced inflammation compared to WT
mice, while the presence of the ER-retained T55I mu-
tant on Cx32 KO background further exacerbates
these abnormalities.
LPS-induced neuroinflammation impairs motor
performance and coordination
We investigated motor performance and coordination
comparing LPS and saline treated animals by using two
behavioral tests, the foot slip and rotarod test (n = 18 per
genotype, n = 9 saline, n = 9 LPS). When tested 4 h after
injection LPS-treated animals from all three genotypes
fell off the rotarod much sooner than the saline treated
animals at both speeds tested (Fig. 2a–b). They also took
longer to complete the 50 steps trial during the foot-slip
test with a higher number of miss-steps compared to an-
imals receiving saline in all three genotypes (Fig. 2c).
Among LPS treated mice, KO T55I mice showed the
worst performance compared to Cx32 KO and WT
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Fig. 1 Diffuse CNS inflammation induced by systemic LPS injection. Images of fixed longitudinal sections of spinal cord (a–c) and brainstem (d–f) as
indicated immunostained for microglial marker Iba1 (red) 1 week after injection. Nuclei are counterstained with DAPI (blue). LPS activates microglia in
both CNS areas and in all genotypes (WT =wild type; KO = Cx32 KO; KO T55I = Cx32 KO/T55I mutant) compared to saline-injected mice. Scale bars in
a–f: 50 μm. g–j Quantification of Iba1 immunofluorescence (% of total area) in different CNS areas (mean ± SEM) in n = 5 mice per group shows a
significant increase in LPS-injected mice compared to controls in all areas studied across all genotypes. KO T55I tissues show the highest
levels of activated microglia (data shown in Additional file 3: Table S1). Immunoblot analysis of Iba1 levels (band at 17 kDa) in brainstem
lysates from WT, KO and KO T55I-(LPS) and saline-injected (S) mice, as indicated (k) and quantification (l) of Iba1 levels (specific band intensity,
normalized for loading with tubulin re-blotting) confirms a significant elevation in LPS compared to saline injected mice of all genotypes, with the
highest elevation in KO T55I mice (only significant values are shown, Student’s t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001, Bonferroni corrected)
Olympiou et al. Acta Neuropathologica Communications  (2016) 4:95 Page 6 of 17
mice, and in turn Cx32 KO mice performed worse than
WT mice. Thus, LPS-induced inflammation affected sig-
nificantly the motor performance in all genotypes but
more severely the Cx32 KO expressing the T55I mutant
than the simple KO or the WT groups (Additional file 6:
Table S2). Interestingly, even at baseline in saline treated
groups, Cx32 KO and even more T55I KO mice showed
worse motor performance than WT animals. Thus,
Cx32 KO and even more T55I KO mice show deficits
in motor performance and coordination compared to
WT mice already at baseline, but in addition a more
severe impairment of their performance after LPS-
induced inflammation, indicating a higher vulnerability
under stress conditions.
LPS induced neuroinflammation does not cause
demyelination or blood-brain barrier disruption in Cx32
mutant mice
To clarify whether the observed inflammatory changes
and impaired motor function could be caused by demye-
lination in the CNS of Cx32 mutant mice, we examined
myelination by immunohistochemistry and immunoblot
analysis. Immunostaining for myelin basic protein
(MBP) and the axonal marker RT97, as well as for
myelin oligodendrocyte glycoprotein (MOG), showed
preservation of myelin immunoreactivity in different
areas of the CNS, including the brain at the level of
the corpus callosum (Additional file 7: Figure S5a–l),
cerebellum and spinal cord (data not shown) in LPS-
injected mice without significant change compared to
saline-injected controls. In addition, immunoblot ana-
lysis confirmed that MBP levels assessed in brainstem
lysates were not significantly altered in LPS-injected
compared to control mice from all three genotypes
(Additional file 7: Figure S5m–o). Thus, demyelin-
ation is unlikely to contribute to the observed pheno-
type of LPS-injected Cx32 mutant mice.
Given the increased CNS inflammation in Cx32 KO
and KO T55I mice we also examined whether blood-
brain barrier (BBB) disruption could play a role in CNS
phenotypes in Cx32 mutant mice following systemic
inflammation induced by LPS. We therefore examined
expression of fibrinogen and fibronectin, two major BBB
markers [53], on fixed brain tissues comparing LPS to
saline treated tissues for each genotype. We found no
evidence of BBB disruption in KO or KO T55I animals
injected with LPS compared to WT and saline controls
(Additional file 8: Figure S6).
LPS-induced systemic inflammation disrupts
oligodendrocyte gap junction formation in the CNS
In order to evaluate whether LPS induced neuroinflam-
mation disrupts oligodendrocytic GJ formation, which in
Cx32 KO mice depends mainly on Cx47, we investigated
by double immunofluorescence staining the expression
of Cx47 in CC1-stained oligodendrocytes in different
CNS areas including the gray and white matter of the
spinal cord (Additional file 9: Figure S7 and Additional
file 10: Figure S8), brainstem (Fig. 3), and cerebellum
(data not shown). Cx47, which is normally expressed
in cell bodies and proximal processes of all oligoden-
drocytes throughout the CNS [27], was markedly re-
duced in inflamed brainstem, cerebellum and spinal
cord, compared to saline controls in all three geno-
types studied. This disruption of Cx47-formed GJs
was associated with diffuse Cx47 immunoreactivity
intracellularly in oligodendrocytes (Fig. 3, Additional
file 9: Figure S7, Additional file 10: Figure S8 and
Fig. 2 Impaired motor performance in LPS-injected mice. Bar charts representing the effect of LPS-induced neuroinflammation on motor performance
examined by rotarod test at 12 rotations per minute (RPM) (a) and at 20 RPM (b) as well as by Foot-slip test (c) in WT, Cx32 KO, and KO T55I mice, as
indicated. Time required for the animal to fall off the rotarod was recorded using a timer. Saline injected animals of all three genotypes were able to
stay much longer on the rotarod compared to LPS injected animals at both speeds tested (a, b). Even at baseline levels KO T55I performed worse that
simple KO animals, while WT animals outer-performed KO animals both in control and in LPS groups (data shown in Additional file 6: Table S2). Foot-slip
analysis (c) revealed that LPS-injected animals showed more missteps compared to saline-injected controls of all three genotypes. Additionally, more
missteps were shown by Cx32 KO compared to WT mice, and by T55I KO compared to simple KO mice, both at baseline and after LPS (Student’s
t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001, Bonferroni corrected)
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Additional file 11: Figure S9). Loss of Cx47 GJ pla-
ques was not due to loss of oligodendrocytes since
double staining with the oligodendrocyte marker CC1
along with quantification of Cx47 GJ plaques per
oligodendrocyte confirmed that oligodendrocytes were
not reduced in numbers, but showed severely reduced
Cx47 GJ plaques per individual cell, in all CNS areas
from LPS-injected mice examined.
Although we did not observe any significant reduction
in the numbers of CC1-positive oligodendrocytes in LPS
tissues we further investigated by double immunostain-
ing with CC1 and caspase-3 whether LPS induced any
oligodendrocyte apoptosis in WT or Cx32 mutant mice.
This analysis showed that caspase-3 immunoreactivity
was not increased in the CNS of LPS-injected WT,
Cx32 KO, or T55I KO mice compared to saline controls
(Additional file 12: Figure S10). Thus, LPS-induced in-
flammation causes loss of Cx47 GJ plaques in oligoden-
drocytes but no oligodendrocyte loss or apoptosis, up to 1
week after injection.
LPS-induced neuroinflammation disrupts astrocyte to
oligodendrocyte gap junctions
To further clarify the cause of the extensive loss of Cx47
GJs observed in LPS treated mice, we also examined the
expression and GJ formation by Cx43, the main astro-
cytic partner of Cx47. Double immunostaining for Cx43
and Cx47 revealed a marked loss of Cx43 formed GJs in
Fig. 3 Disruption of oligodendrocyte gap junctions (GJs) in inflamed brainstem. a–f Coronal brainstem sections immunostained for oligodendrocyte
marker CC1 (green) and Cx47 (red) with nuclear DAPI staining (blue). In KO T55I tissues all oligodendrocytes transgenically express enhanced green
fluorescent protein (EGFP) and were not stained with CC1. There is a reduction of Cx47 formed GJ plaques at oligodendrocyte cell bodies and
proximal processes in LPS-injected mouse tissues (b, d, f) compared to saline controls (a, c, e) associated with increased intracellular signal of
Cx47 suggesting diffusion (insets in d, f). Scale bars in a–f: 10 μm. Counts of GJ plaques per oligodendrocyte confirm a significant reduction
in LPS tissues compared to controls in all genotypes (h, j, l), whereas total oligodendrocyte numbers remain unchanged in LPS compared to control
groups (g, i, k) (Student’s t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001)
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both gray and white matter of the spinal cord in LPS-
injected mice compared to controls. There was de-
creased immunoreactivity of Cx43 along with a patchy
appearance in all areas examined, most severely in KO
T55I LPS spinal cord (Fig. 4 and Additional file 13:
Figure S11, Additional file 14: Figure S12 and Additional
file 15: Figure S13). Cx43 GJ plaques that normally ap-
pear denser around oligodendrocyte cell bodies and co-
localize with Cx47 were markedly reduced, associated
with reduction of Cx47 GJ plaques and diffuse Cx47
cytoplasmic signal. This disruption of Cx43 expression
was not associated with either astrocyte loss or astroglio-
sis, as shown by double immunostaining with the astro-
cyte marker GFAP, which demonstrated preserved
pattern of astrocyte immunoreactivity (Additional file
16: Figure S14). To further corroborate these findings,
we counted the total number of Cx43 as well as Cx47
GJ plaques in spinal cord white (Fig. 4) and gray matter
(Additional file 13: Figure S11), as well as in the brain-
stem (Additional file 14: Figure S12). This analysis
Fig. 4 Disruption of astrocyte to oligodendrocyte GJs in inflamed spinal cord white matter (WM). a–f Fixed longitudinal spinal cord WM sections
immunostained for astrocytic Cx43 (green) and Cx47 (red) with nuclear DAPI staining (blue) show reduced overall Cx43 immunoreactivity in
LPS-injected spinal cord tissues (b, d, f) of all genotypes compared to saline controls (a, c, e). Fewer GJ plaques are formed by both Cx43
as well as Cx47 at oligodendrocyte cell bodies and proximal processes, which are often colocalized in control more than in LPS treated
mice. In oligodendrocytes from LPS treated mice there is often a diffused signal of Cx47 intracellularly (inset in f). Scale bars in a–f: 10 μm.
Counts of GJ plaques formed by Cx43 (g, I, k) as well as by Cx47 (h, j, l) confirm a significant reduction in LPS treated mice of all genotypes
(Student’s t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001)
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confirmed the significant reduction of Cx43 GJ plaque
numbers similar to Cx47 in all examined CNS areas
from LPS-injected mice compared to controls from
all genotypes.
Quantitative immunoblot analysis of Cx43 levels in
brainstem lysates showed that Cx43 was significantly re-
duced in Cx32 KO and KO T55I LPS groups compared
to saline controls (Fig. 5a–c), whereas in LPS treated
WT mice the Cx43 reduction was not significant. Thus,
there is a significant disruption or increased recycling/
degradation of Cx43 expression and GJ formation in as-
trocytes that may play a role in the loss of Cx47 GJs in
oligodendrocyte of Cx32 KO mice in the setting of LPS-
induced neuroinflammation. In contrast, Cx47 protein
levels assessed by immunoblot analysis were not signifi-
cantly altered in LPS-treated mice (Fig. 5d–f ), suggesting
that Cx47 was initially retracted from GJs but remained
in the cytoplasm. Indeed, as shown below the loss of oli-
godendrocytic Cx47 GJ plaques in this LPS model of
CMT1X appears to follow the loss of Cx43 GJs in astro-
cytes (at least at the level of transcription).
Downregulation of Cx43 precedes the loss of Cx47 in
LPS-injected Cx32 mutant mice
To clarify which of the connexin partners at A/O GJs is
affected first by LPS-induced neuroinflammation in
Cx32 mutant mice, we examined their expression by
Real-time PCR analysis. These experiments revealed that
Cx43 mRNA levels were significantly reduced in CNS
tissues from KO and KO T55I LPS-injected mice com-
pared to controls, while a non-significant reduction was
also observed in the WT group. Comparison of baseline
Cx43 mRNA levels between the three genotypes at base-
line (saline) showed no significant difference. However,
among LPS-treated groups Cx43 expression was signifi-
cantly more reduced in KO T55I than in simple KO and
the WT groups (Fig. 5g). We also analyzed Cx47 mRNA
expression levels comparing LPS-injected to control
Fig. 5 Loss of Cx43 in the brainstem following LPS-injection. Immunoblot analysis (blots and quantification diagrams) of Cx43 (a–c) and Cx47
(d–f) levels in brainstem lysates from groups (n = 4 per genotype and treatment group) of WT (a, d), Cx32 KO (b, e) and KO T55I (c, f) LPS or
saline (S) injected mice, as indicated. All blots were re-probed for GAPDH for loading control and normalized bands were measured using
Tinascan software. Compared to saline controls, Cx43 levels (specific band at 43 kDa) are reduced in the brainstem of LPS-injected Cx32 KO
and KO T55I mice. In contrast, Cx47 levels do not show any significant changes in LPS treated mice in any of the genotypes (d, e, f) (*:p < 0.05,
Student’s t-test). Real-time PCR analysis of Cx43 (g) and Cx47 (h) expression in LPS- compared to saline-treated mice shows a significant reduction of
Cx43 expression in LPS injected tissues of KO and KO T55I groups, while the reduction in the WT group was non-significant. The KO T55I
group showed the strongest reduction after LPS compared to the other genotypes. In contrast, Cx47 mRNA levels showed no significant
changes in LPS-treated mice (Student’s-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001, Bonferroni corrected)
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mice in all genotypic groups both at baseline and after
LPS injection. Although we observed a small reduction
in the expression of Cx47 in the T55I KO groups, there
was no significant difference compared to WT or KO
mice or in LPS compared to control groups (Fig. 5h).
Thus, astrocytic Cx43 appears to be downregulated
under inflammatory conditions with reduction of GJ
channels. Loss of Cx43 is associated with reduction of
oligodendrocyte Cx47 GJs and A/O connectivity, and
diffusion of Cx47 away from the cell membrane, since
Cx47 mRNA and protein levels are not reduced. These
alterations appear to be more severe in the Cx32 KO
T55I mutant than in the simple Cx32 KO mouse.
The expression of the ER-retained T55I mutant triggers
ER-stress under inflammatory conditions
To further examine whether the presence of the T55I
mutant, which is known to be retained intracellularly in
the ER in vitro and in vivo [29, 57], could cause any add-
itional cellular stress exacerbating the observed LPS-
induced changes, we analyzed the expression of early
ER-stress markers CHOP, Fas and BiP by immunohisto-
chemistry, and further examined BiP expression by im-
munoblot and Real-time PCR. Immunostaining for the
apoptotic marker Fas, which is induced by early ER
stress events [67], revealed increased CHOP and Fas im-
munoreactivity mostly in white matter oligodendrocytes
of LPS treated KO T55I mice compared to their saline
controls and to a lesser degree in KO and WT mice
(Fig. 6a–c, Additional file 17: Figure S15). Likewise, BiP
immunoreactivity was increased in spinal cord white
matter in LPS treated mice but most prominently in KO
T55I (Fig. 6d–f ). Real-time PCR analysis confirmed at
the mRNA level that BiP expression was significantly in-
creased in the inflamed CNS of LPS-treated Cx32 KO
mice, but this increase was much more pronounced in
KO T55I mice (Fig. 6g). Quantitative immunoblot re-
sults revealed that BiP protein levels were significantly
elevated in the brainstem of KO T55I LPS-treated com-
pared to saline control mice but not in WT or Cx32 KO
mice (Fig. 6h–j). Thus, neuroinflammation appears to
cause ER stress in oligodendrocytes, and this is exacer-
bated in Cx32 KO mice compared to WT mice, while
the presence of the ER-retained T55I mutant increases
even further the ER stress response.
Discussion
Our study provides further insights into the cellular and
molecular mechanisms underlying the intriguing CNS
phenotypes in patients with CMT1X. First, we show that
in the absence of Cx32 in Cx32 KO mice there is a
higher vulnerability to inflammation, since the associ-
ated downregulation of astrocytic Cx43 leads to reduc-
tion of Cx47-formed O/A GJ channels and impaired
oligodendrocyte connectivity to the glial GJ network.
This mechanism is independent from the presence Cx32
mutants. Second, we demonstrate that the presence of
the ER-retained T55I mutant in a Cx32 KO background
further increases oligodendrocyte vulnerability to inflam-
matory stress, through an increased ER-stress response.
This mechanism could be additive to the disruption of
A/O GJs, leading to even more severe CNS dysfunction.
The most common trigger of the CNS phenotype re-
ported in CMT1X patients besides high altitude travel
was a febrile systemic illness such as upper respiratory
infection, fever of uncertain cause, pneumonia or gastro-
enteritis in at least half of all cases (reviewed by [2]). In
order to reproduce the CNS phenotype induced by
systemic inflammation in CMT1X patients, we gener-
ated a model of systemic inflammation induced in Cx32
mutant mice by intraperitoneal injections of LPS. We
confirmed the generalized inflammatory response by
detecting transient elevation in blood of two pro-
inflammatory cytokines, TNF-α and IL-6, as shown in
other studies [14]. LPS activates liver cells to produce
cytokines in the periphery, which in turn activate
humoral and neural communication pathways [12, 55, 62]
and induce glial cells in the CNS to produce the
same inflammatory cytokines. Activation of microglia,
the resident immune cells of the brain, results in syn-
thesis of additional TNF-α and other cytokines and
leads to persistent neuroinflammation [54]. Likewise,
in our study we observed diffusely activated microglia
in different CNS areas including the cerebrum, cere-
bellum, brainstem and spinal cord and Iba1 immuno-
blots from brainstem lysates confirmed increased
microglial activation induced by systemic LPS injec-
tion. Thus, LPS treatment provides a relevant model
for the CNS phenotypes in CMT1X patients.
The LPS model described here was characterized by
early sickness behavior and transient weight loss, similar
to the phenotype reported in other models [19]. In
addition, we examined motor behavior by rotarod and
foot-slip test behavioral analysis, showing a marked im-
pairment in LPS-treated mice compared to saline con-
trols as shown in similar studies [62]. Moreover, the
comparison of the three genotypes showed that Cx32
KO mice are more vulnerable to neuroinflammation
than WT mice, and KO T55I show even more vulner-
ability than do simple KO mice. Thus, LPS-induced neu-
roinflammation affects motor performance even more in
the presence of the T551 mutant, suggesting additional
gain of function mechanisms that could explain the CNS
phenotypes in some CMT1X patients.
Despite the diffuse response of the innate immunity in
the CNS, we found no disruption of BBB, inflammatory
cell infiltrates in the peripheral nervous system, oligo-
dendrocyte loss, or demyelination in Cx32 mutant mice,
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indicating that these are unlikely mechanisms in CNS
phenotypes occurring in CMT1X patients. Our results
are therefore in agreement not only with the clinical
course in CMT1X patients, who show early recovery,
but also with the available MRI studies that have shown
transient, nearly symmetric, diffuse T2 and fluid-
attenuated inversion recovery (FLAIR) hyperintensities
and restricted diffusion signal abnormalities, but no con-
trast enhancement and no typical demyelinating lesions
[2, 49, 65]. The clinical and MRI characteristics of CNS
involvement in CMT1X patients are in fact consistent with
transient disruption of the gap junctional communication
between oligodendrocytes and astrocytes leading to inabil-
ity of these cells to regulate fluid exchange.
Astrocytes appear to play a role in the link between
neuroinflammation or metabolic stress and CNS pheno-
types in CMT1X as they are closely connected to oligo-
dendrocytes through GJs. Oligodendrocytes express
Cx47 throughout the CNS, and in many areas also Cx32
[27]. Besides their participation in A/O GJs, Cx32 and
Cx47 also form homotypic channels between oligoden-
drocytes. Cx29 is a third oligodendrocyte connexin that
appears to form only hemichannels and does not partici-
pate in intercellular GJs [3]. Astrocytes express Cx43 in
Fig. 6 Systemic inflammation induces ER-stress most severely in the CNS of Cx32 KO T55I mutant mice. Images of brainstem sections focusing on
white matter areas from saline (S) or LPS treated WT (a), Cx32 KO (b) and KO T55I (c) mice as indicated, immunostained with the ER-stress and
pro-apoptotic marker Fas (red). Cell nuclei are stained with DAPI (blue). Higher magnification details of oligodendrocytes are shown in insets. Fas
immunoreactivity is increased in LPS tissues, most prominently in KO T55I brainstem (c). Likewise, spinal cord longitudinal sections immunostained
for the ER-stress marker BiP (red) (d–f) show increased immunoreactivity in LPS-treated mice compared to saline controls, especially in KO T55I
mice. Scale bars in a-c: 30 μm; in d–f: 10 μm. g Real-time PCR analysis of BiP expression comparing LPS to saline groups from WT, KO and KO
T55I animals, as indicated, shows that BiP mRNA is elevated in LPS tissues compared to saline controls in Cx32 KO and even more in KO T55I
groups but not in WT mice. Direct comparison of LPS groups from all three genotypes confirms elevation of BiP expression in Cx32 KO and KO
T55I mice compared to WT mice, and in KO T55I significantly more than in the simple KO group. h–j Immunoblot analysis of BiP levels (BiP specific
band at 74 kDa) in brainstem tissue lysates (n= 4 mice per genotype and treatment group) from LPS compared to saline treated WT (h), KO (i) and KO
T55 (j) mice as indicated, shows significant elevation of BiP levels only in the KO T55I LPS group. Blots were re-probed for tubulin or GAPDH for loading
control and normalized BiP band intensity was quantified with Tinascan software (Student’s-test, *:p< 0.05, **:p < 0.01, ***:p< 0.001, Bonferroni corrected)
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both gray and white matter and Cx30 mainly in the gray
matter, connecting with other astrocytes through
homotypic (Cx43/Cx43 and Cx30/Cx30) GJs as well
as with oligodendrocytes with heterotypic (Cx43/Cx47
and Cx30/Cx32) GJs [4, 22, 43, 48, 73]. Among these
channels, Cx43/Cx47 GJs play the major role especially in
the white matter.
Several experimental mouse models have been gener-
ated to clarify the role of each of these astrocyte and
oligodendrocyte connexins in the CNS. Single KOs
showed minimal CNS pathology leading to the overall
conclusion that there is partially overlapping function of
connexins in both cell types. However, when more than
one connexin and type of GJ channel is disrupted, severe
demyelinating pathology develops. Thus, mice lacking
either Cx32 or Cx47 develop minimal CNS pathology
and no obvious CNS phenotype, but loss of both oligo-
dendrocyte connexins in Cx32/Cx47 double KO mice
leads to severe and early CNS demyelination [41, 46].
Likewise, deletion of both astrocyte connexins (Cx30
and Cx43) [35], or at least one partner of each of the
two A/O GJ types, either Cx43 and Cx32 [40], or Cx30
and Cx47 [69] results in severe demyelination and vacu-
olation because in each case all A/O GJs are completely
disrupted. In contrast to these double KO models with
congenital and complete lack of oligodendrocyte GJ
channels, in our LPS model induced in Cx32 deficient
mice there was only partial reduction of Cx47 GJs
after completed development, which did not cause de-
myelination. This underscores the important role of
Cx47 in oligodendrocytes with expression as starting
at earlier stages of their development and differenti-
ation [41, 46], as early as P7 [66], including in oligo-
dendrocyte precursor cells [37].
Of particular relevance to the current study and the
mechanism of CNS phenotypes in CMT1X is the Cx32/
Cx43 double KO model, which revealed that in the ab-
sence of Cx32 GJs (as in CMT1X patients) oligodendro-
cytes depend exclusively on Cx43/Cx47 GJs. When Cx43
is also disrupted, the stability of Cx47 on oligodendro-
cyte cell membrane is impaired leading to loss of Cx47
formed GJs, and consequently to complete disconnec-
tion of oligodendrocytes [40]. In our LPS model we ob-
serve a clear downregulation of Cx43 in astrocytes with
early reduction of mRNA levels. In contrast, there are
no significant changes in Cx47 mRNA and protein
levels, despite reduction of Cx47 GJ plaques and diffu-
sion in the cytoplasm. This pattern of secondary disrup-
tion of Cx47 GJ plaques following the downregulation of
astrocytic Cx43 during acute inflammation has also been
shown in previous studies using the EAE model [36]. As
in the EAE model, loss of Cx47 GJs was not associated
with loss of oligodendrocytes, further supporting the
secondary mechanism of Cx47 diffusion into the
cytoplasm [40]. The downregulation of Cx43 in the LPS
model likely reflects a non-specific astrocytic reaction to
diverse CNS injury, including inflammation, and has
been shown in EAE [10, 36, 61], ischemia [32] and abscess
[23] models and is likely mediated by pro-inflammatory
cytokines [13, 15, 21]. Thus, it is plausible to hypothesize
that in CMT1X patients, in whom oligodendrocyte GJ
connectivity depends only on Cx43/Cx47 GJs, down-
regulation of Cx43 as part of an astrocyte reaction to
inflammatory or metabolic stress will disrupt Cx47 in
oligodendrocytes and lead to transient encephalopathy.
Our previous studies in EAE models showed that Cx43
downregulation is a transient reaction followed by re-
expression at later stages [36], and this would be in
keeping with the reversibility of CNS phenotypes in
CMT1X patients. Nevertheless, inflammation could
also directly affect Cx47 expression independently of
astrocyte reaction and Cx43 loss, since pro-inflammatory
cytokines have been shown to induce ER-stress response
in oligodendrocytes [34].
Cx32 KO mice with or without the presence of the
T55I mutant showed a worse phenotype than WT mice.
One explanation is the higher CNS inflammatory load
reflected in the amount of microglia activation. This
would also explain why Cx43 was more severely decreased
in these mutants, although not an oligodendrocyte con-
nexin. A pro-inflammatory environment associated with
elevated cytokine levels at baseline has been recently
documented in Cx32/Cx47 dKO mice suggesting that
connexin deficiency in oligodendrocytes drives CNS in-
flammation independently of external immune triggers
[74]. The exacerbated phenotype of Cx32 mutant mice
following LPS treatment may also result from effects of in-
flammation on neurons and axons directly or indirectly,
for example through astrocyte dysregulation of synaptic
function [51], independently of the effects in oligodendro-
cytes. Previous studies showed exacerbated axonal loss in
Cx32 KO compared to WT mice after EAE induction
[36], which may result from disturbed signaling [68] and
energy supply [72], as well as axonal neurofilament de-
phosphorylation [71] in the absence of Cx32 GJs along
myelinated fibers. Thus, axons of Cx32 KO mice may have
increased vulnerability to inflammatory stress.
The next question is why the presence of the T55I
mutant exacerbates all CNS manifestations in our LPS
model, including the inflammatory, behavioral, and con-
nexin abnormalities. Although our previous studies in
Cx32 KO T55I mice failed to show a dominant effect be-
yond the simple KO phenotype under normal conditions
[57], LPS-induced neuroinflammation affected more se-
verely the KO T55I than the “simple” KO and WT mice.
Thus, the presence of the T55I mutant may render
oligodendrocytes more vulnerable to inflammation. We
believe that this is because the T55I mutation causes
Olympiou et al. Acta Neuropathologica Communications  (2016) 4:95 Page 13 of 17
retention of misfolded Cx32 in the ER leading to ER-stress
response especially under inflammatory conditions, which
in turn exacerbates further oligodendrocyte homeostasis.
LPS induced a significant elevation of BiP expression espe-
cially in KO T55I mice, as opposed to WT and Cx32 KO
mice, although Cx32 KO mice also showed a significantly
higher ER-stress response compared to WT mice. Previ-
ous studies have shown that upon TNF-α release, micro-
glia activation and ER stress are induced in the CNS and
that ER stress blockers suppress the induced inflammation
[39]. Involvement of ER stress has also been demonstrated
in LPS-induced inflammation and inhibition of ER stress
ameliorated LPS-induced lung injury through modulation
of several cytokine pathways [25]. In addition we found in-
creased Fas immunoreactivity induced by LPS injection
mostly in KO T55I LPS treated mice compared to simple
KO or WT. ER stress induces Fas and mitochondrial
apoptosis pathways through elevation of cytosolic calcium
[67]. In our study, both the ER stress marker BiP and
CHOP, along with the pro-apoptotic marker Fas, were
mostly elevated in the presence of the T55I mutant sug-
gesting that under stress conditions intracellularly retained
Cx32 mutants may exacerbate ER stress upon neuroin-
flammation, leading to the development of CNS pheno-
types in CMT1X patients. This effect may be additive to
the disruption of A/O GJs described above, making CNS
manifestations more likely in patients with intracellularly
retained mutants as initially hypothesized [29], although
they can also occur in the absence of any Cx32 [56].
Conclusion
In conclusion, the work presented here provides evidence
that LPS-induced systemic and CNS inflammation causes
oligodendrocyte dysfunction associated with disruption of
the main A/O GJs resulting from downregulation of astro-
cytic Cx43 and diffusion of Cx47. Moreover, there is an ex-
aggerated ER stress response related to the intracellularly
retained Cx32 mutant. Our study provides a relevant model
and a mechanistic explanation for the development of CNS
phenotypes in CMT1X. In patients with Cx32 mutations
the already compromised oligodendrocyte homeostasis
causing subclinical manifestations at baseline conditions,
may decompensate under conditions of metabolic and in-
flammatory stress producing the transient encephalopathy
manifestations.
Additional files
Additional file 1: Figure S1. 1 LPS induces IL-6 and TNF-α increase in
Cx32 KO mice. a-b: Graphs representing concentration course of IL-6 before
(0 h) as well as 4, 24, and 96 h after saline (a) or LPS (b) injection as
measured at 450 nm with ELISA. Saline did not cause any significant
systemic inflammation (baseline inflammation: 0.14 pg/mL, 4 h after
injection: 0.23 pg/mL), whereas a marked increase 4 h after LPS injection
(935.1 pg/mL) was found. c-d: Levels of TNF-α before (0 h) as well as after
(4, 24, 96 h) saline (c) and LPS (d) injection; saline did not cause any
inflammatory response (baseline: 0.21 pg/mL, at 4 h: 0.22 pg/mL)
whereas LPS injection caused a marked TNF-α increase (4 h after injection:
22.08 pg/mL). (TIF 12301 kb)
Additional file 2: Figure S2. LPS causes diffuse CNS inflammation in
the cerebellum and cerebral cortex. Images of fixed coronal sections of
cerebellum (a-f) and cerebral cortex (g-l), as indicated, immunostained
for microglial marker Iba1 (red). Cell nuclei are counterstained with DAPI
(blue). Microglia are diffusely activated in both CNS areas and in all genotypes
in LPS (b, d, f, h, j, l) compared to saline (a, c, e, g, i, k) injected mice. Scale
bars: 50 μm. (TIF 7715 kb)
Additional file 3: Table S1. Quantification of Iba1 immunoreactivity in
different CNS areas of saline and LPS treated WT, Cx32 KO (KO) and T55I
KO mice. (DOCX 22 kb)
Additional file 4: Figure S3. Localization of the T55I Cx32 mutant in
the endoplasmic reticulum in oligodendrocytes. This is an image of
spinal cord white matter longitudinal sections from a Cx32 KO T55I
mutant mouse (saline control) double labeled with antibodies to Cx32
(green) and ER marker BiP (red). Cell nuclei are stained with DAPI (blue).
Overview image is shown on the left and higher magnification images
of cells in separate channels are shown on the right. The T55I mutant
is retained intracellularly in oligodendrocytes and colocalizes in the
perinuclear cytoplasm with the ER marker, indicating retention in the
ER. No GJ-like plaques are formed by the mutant on the cell membrane.
Scale bar: 10 μm. (TIF 16462 kb)
Additional file 5: Figure S4. LPS injection does not cause inflammatory
changes in the peripheral nervous system. Fixed longitudinal sections of
sciatic nerves (a-f) and lumbar spinal roots (g-l) from LPS-injected and saline
control mice from all three genotypes as indicated, immunostained with
T-cell marker CD3 (red) and macrophage marker CD68 (green). Cell nuclei
are stained with DAPI (blue). There is no difference in inflammatory cell
immunoreactivity between treatment groups in any of the genotypes. No
CD3+ cells are seen, whereas 1–2 CD68+ macrophages are present in all
tissues regardless of the genotype and treatment condition. Scale bars in
a-f: 30 μm; in g-l: 20 μm. (TIF 50275 kb)
Additional file 6: Table S2. Results of behavioral testing in saline control
and LPS treated WT, Cx32 KO (KO) and T55I KO mice. (DOCX 22 kb)
Additional file 7: Figure S5. Lack of CNS demyelination in LPS-injected
Cx32 mutant mice. a-l: Images of brain sections at the level of the corpus
callosum immunostained with axonal marker RT97 (green) in combination
with myelin marker MBP (red) (a-f) or with myelin marker MOG (g-l) and
DAPI nuclear staining (blue). There is no apparent alteration of myelin
immunoreactivity in the brains of LPS-injected mice (b, d, f, h, I, l)
compared to saline controls (a, c, e, g, j, k) from all three genotypes,
as indicated. Scale bar: 50 μm. m-o: Immunoblot analysis of MBP levels in
brainstem tissue lysates show no significant change induced by LPS
injection (LPS) compared to saline-injected mice (S) in WT (m), Cx32
KO (n) or KO T55I (o) groups as indicated. All blots were re-probed
for tubulin to demonstrate the loading, and quantification of normalized
MBP band intensity is shown next to each blot. (TIF 19222 kb)
Additional file 8: Figure S6. LPS induced neuroinflammation does not
cause blood brain barrier (BBB) disruption in Cx32 mutant mice. These
are images of fixed coronal brain sections, immunostained with blood
brain barrier markers fibronectin (green) (a-f) or fibrinogen (red) (g-l) and
counter stained with DAPI (blue). There is no apparent disturbance of
BBB integrity in the brain of LPS treated (b, d, f, h, j, l) compared to saline
treated (a, c, e, g, i, k) mice from any of the three genotypes, as indicated.
Linear fibrinogen immunoreactivity in brain parenchyma represents small
blood vessels. Scale bar: 50 μm. (TIF 9451 kb)
Additional file 9: Figure S7. LPS disrupts oligodendrocyte GJs formed
by Cx47 in spinal cord gray matter. a-f: Fixed longitudinal spinal cord gray
matter sections immunostained with oligodendrocyte marker CC1 (green)
and Cx47 (red) and counterstained with DAPI (blue). In KO T55I tissues all
oligodendrocytes transgenically express EGFP and were not stained with
CC1. Cx47 immunoreactivity and GJ plaque formation at oligodendrocyte
cell bodies and proximal processes is reduced in LPS-treated mice (b, d, f)
of all genotypes compared to their saline controls (a, c, e). Scale bar: 20 μm.
Counts of Cx47 GJ plaques per individual oligodendrocyte shows a significant
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reduction in LPS compared to saline treated mice (h, j, l), whereas
the number of CC1/EGFP-positive oligodendrocytes per genotype
as indicated shows no significant reduction in LPS compared to saline
treated mice (Student’s t-test, *:p< 0.05, **:p< 0.01, ***:p< 0.001). (TIF 8996 kb)
Additional file 10: Figure S8. LPS disrupts oligodendrocyte Cx47 GJs
in spinal cord WM. a-f: Fixed longitudinal spinal cord WM sections
immunostained for CC1 (green) and Cx47 (red) and counterstained
with DAPI (blue). In KO T55I tissues all oligodendrocytes transgenically
express EGFP and were not stained with CC1. Cx47 immunoreactivity and
GJ plaque formation at oligodendrocyte cell bodies and proximal processes
is reduced in LPS treated mice of all genotypes (b, d, f) compared to their
saline controls (a, c, e), with increased cytoplasmic immunoreactivity
insets in d, f). Scale bar: 10 μm. Quantification of CC1/EGFP-positive
oligodendrocytes per genotype as indicated (g, i, k) shows no significant
reduction in LPS treated compared to saline groups, whereas quantification
of Cx47 GJ plaques per individual oligodendrocyte shows significant
reduction in LPS compared to saline treated mice, most severely in KO T55I
(h, j, l) (Student’s t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001). (TIF 9244 kb)
Additional file 11: Figure S9. Disruption of Cx47 GJs in oligodendrocytes.
Confocal microscopy images of cerebellar white matter sections from saline
(a) and LPS (b) treated mice immunostained for Cx47 (red). Oligodendrocytes
are green fluorescent because they transgenically express EGFP. Compared to
saline control tissue with numerous Cx47 formed GJ plaques (open
arrowheads) on the surface of oligodendrocytes (a), there is loss of
plaques and increased intracellular immunoreactivity (arrow) in LPS
tissue (b). Scale bar: 10 μm. (TIF 2639 kb)
Additional file 12: Figure S10. Lack of oligodendrocyte apoptosis after
LPS-induced neuroinflammation in Cx32 mutant mice. Images of fixed
longitudinal sections of cerebellar white matter double stained with
apoptosis marker caspase-3 (red) along with oligodendrocyte marker CC1
(green) and counter stained with DAPI (blue). Caspase-3 immunoreactivity
does not increase in LPS-tissues (b, d, f) compared to saline controls
(a, c, e) in any of the three genotypes, indicating lack of oligodendrocyte
apoptosis up to 1 week after LPS-induced inflammation. Scale bar:
50 μm. (TIF 8299 kb)
Additional file 13: Figure S11. LPS disrupts Cx43 and Cx47 GJs in
spinal cord gray matter. a-f: Fixed longitudinal spinal cord gray matter
immunostained for Cx43 (green) and Cx47 (red) and counterstained with
nuclear marker DAPI (blue). Cx43 immunoreactivity is reduced in LPS-
injected mice (b, d, f) of all genotypes compared to saline controls
(a, c, e) as indicated. Scale bar in a-f: 10 μm. Counts of Cx43 GJs in
all three genotypic groups confirms significant reduction in LPS injected
compared to saline treated mice (g, i, k). Likewise, Cx47 GJ plaque numbers
per area are also reduced in all genotypes after LPS injection (h, j, l)
(Student’s t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001). (TIF 14930 kb)
Additional file 14: Figure S12. LPS disrupts Cx43 and Cx47 GJ formation
in the brainstem. a-f. Fixed coronal brainstem sections immunostained for
Cx43 (green) and Cx47 (red) along with nuclear DAPI staining (blue). Cx43
immunoreactivity is reduced in the brainstem of LPS-injected mice (b, d, f)
of all genotypes compared to their controls (a, c, e), associated with
reduction of Cx47 GJ plaques. Scale bar: 10 μm. Quantification of total Cx43
GJ plaques confirms that LPS causes significant reduction of both Cx43 (g, i,
k), as well as Cx47 formed GJs (h, j, l) in all three genotypic groups (Student’s
t-test, *:p < 0.05, **:p < 0.01, ***:p < 0.001). (TIF 11587 kb)
Additional file 15: Figure S13. Disruption of astrocyte and
oligodendrocyte GJs in inflamed cerebellum. a-f: Fixed coronal cerebellar
cortex sections including white matter (WM) surrounded by the granule cell
layer (GCL) show double immunostaining with Cx43 (green), Cx47 (red) and
nuclear DAPI staining (blue). Immunoreactivity of both Cx43 and Cx47 is
reduced in LPS treated mice of all genotypes (b, d, f) compared to
their saline controls (a, c, e) as indicated. Insets showing higher magnification
of individual oligodendrocytes show reduction of GJ plaque formation by
Cx43 and Cx47 at the cell bodies and proximal processes of oligodendrocytes
with a weak diffuse cytoplasmic Cx47 immunoreactivity indicating intracellular
diffusion (f). Scale bar: 50 μm. (TIF 21393 kb)
Additional file 16: Figure S14. LPS does not induce astrocyte loss or
astrogliosis in Cx32 KO or KO T55I mice. These are images of spinal cord
white matter longitudinal sections immunostained with astrocytic marker
GFAP (green) and astrocytic Cx43 (red). Cell nuclei are stained with DAPI
(blue). When comparing saline to LPS treated WT (a, b), KO (c, d) and KO
T55I (e, f) mice there is no apparent change in astrocyte immunoreactivity,
while Cx43 appears to form fewer GJ plaques in LPS treated (b, d, f) compared
to saline treated mice (a, c, e). Scale bar: 50 μm. (TIF 19981 kb)
Additional file 17: Figure S15. Upregulation of ER-stress marker CHOP
in oligodendrocytes of T55I KO mice treated with LPS. These are images
of cerebellar white matter sections from saline (S) and LPS treated WT (a,
b), Cx32 KO (c, d) and KO T55I (e, f) mice, as indicated, immunostained
with oligodendrocyte marker CC1 (green) and ER-stress response
marker CHOP (red). Cell nuclei are stained with DAPI (blue). Details of
oligodendrocytes are shown in insets and separate channels. CHOP
immunoreactivity is detectable in oligodendrocytes of KO T55I mice
treated with LPS (open arrowheads in f) but not in the other treatment
groups. Scale bar: 10 μm. (TIF 13422 kb)
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